This series of bite-sized episodes contains important information you need to navigate the evolving world of Alzheimer’s disease (AD) research. Dr. Marc Agronin and Dr. Richard Isaacson discuss the recent advances in AD and provide practical approaches for prevention, diagnosis, and treatment.
How to Make an Early Diagnosis
How to Make an Early Diagnosis
Welcome to CME on ReachMD. This episode is part of our MinuteCME curriculum.
Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives.
This is CME on ReachMD, and I'm Dr. Marc Agronin. I'm here with my colleague Dr. Richard Isaacson.
So let's dive right in and talk about early diagnosis of Alzheimer's disease. How do we do it? What challenges or barriers might get in the way? And, Dr. Isaacson, I guess I pose it this way: What's the one really critical question that either a caregiver or a person themselves or their physician needs to be asking if there's a concern about cognitive impairment? And if so, then what do we do to try to get at that early diagnosis?
Yeah, so I think in the future where there's going to be a simple blood test, or a simple cognitive test, or a simple test, or a simple something that can deduce this in a much more easier and more effective way. But right now, there's a variety of different tools that we can do. And I think if I had to choose one thing it's to take a detailed clinical history. How is that person doing over the last several months, several years? And how has that change been from their original baseline?
If there's been a change in their ability to recall information and a problem with short-term memory loss that’s been progressive over time, that clinical history, those details really suggest that something could be happening in terms of pathologic decline in the brain. And common things happen commonly; the most common cause of neurodegenerative dementia and short-term memory loss is Alzheimer's disease. And these are things that will allow us to at least say, hmm, maybe we need to think about doing more tests.
So that alone isn't going to be perfect, but we're going to do a physical exam. We, of course, need to do some screening cognitive tests. I wish there was a perfect test. I think a lot of people use the Mini-Mental status exam. It's helpful because everyone's familiar with it, but it's an imperfect test. I do think the MoCA, Montreal Cognitive Assessment, is also an option. And there's other more extensive neurocognitive testing that can help. And then of course, there's Alzheimer's biomarkers; there's brain imaging; there's all sorts of different studies.
But I think when it takes just a few minutes, just talk to the patient, talk to your loved one, and try to understand where were they at baseline? Where have they gone? And what were the exact specific symptoms, the exact changes that the person has observed over time.
Yeah, without question that has to be the mainstay of the treatment. When it comes to neuroimaging, if obviously, we want to be comprehensive, but what's the first priority there in terms of the type of scan and what you would look for on a scan?
Yeah, so, aside from doing the usual screening blood tests, the thyroid check and the B12, and a lot of times, you may find something with the thyroid or the B12, but that's not necessarily going to be the cause of the cognitive decline, but it's always important to rule out. We have to do some sort of brain imaging tests. The American Academy of Neurology guidelines state that we have to do something, whether it's a CAT scan or an MRI. In my clinical experience and in my practice, we always, of course, choose an MRI of the brain. We do thin cuts, thin slices or coronal cuts, through the temporal lobes to actually evaluate is there shrinkage of the memory center, the atrophy of the hippocampus. And if you have that biomarker on a read and you have progressive short-term memory loss, that person could certainly have the earliest stages of Alzheimer's disease.
But in terms of neuroimaging, we can now do biomarkers between an amyloid scan using a PET scan or a tau scan, also using a PET scan. However, these tests are expensive; they have radiation; they're costly. You could do a spinal tap. A spinal tap is something that not everyone is excited about doing. There also is a cost to that, and a procedural cost and time, but that looks for both amyloid and tau in the spinal fluid.
But where I'm really excited about is the emerging area of blood-based biomarkers. And nowadays in the United States in 49 states, we can get the amyloid blood test today. And coming very soon is both an amyloid and tau blood test that has a very good sensitivity and specificity for someone having amyloid in the brain based on a PET scan. So I think this whole era of early diagnosis is going to change quite rapidly as we have this new era of blood-based biomarkers.
I would say this is a key takeaway here. Don't rush to judgment. Just because someone is getting older doesn't mean that automatically they have memory problems. If someone has memory problems, that doesn't automatically mean that they have Alzheimer's disease. The bottom line is that you need this comprehensive evaluation, all the different parts put together. And then critically, you need expert eyes to look at the information to put it together, to synthesize, to take the story over time, and to try to determine what's the best diagnosis.
So, Dr. Isaacson, again, this has been a great bite-sized discussion. Our time is up here. But, everyone, thank you for listening.
Thanks so much.
You have been listening to CME on ReachMD. This activity is provided by Prova Education and is part of our MinuteCME curriculum.
To receive your free CME credit, or to download this activity, go to ReachMD.com/Prova. Thank you for listening.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Marc E. Agronin, MD
Senior Vice President, Behavioral Health
Chief Medical Officer, MIND Institute
Miami Jewish Health
Consulting Fees: Eli Lilly and Company, Otsuka America Pharmaceuticals Inc.
Contracted Research: AgeneBio, Alzheon, Inc, Avanir Pharmaceuticals, Inc, Eli Lilly and Company, F. Hoffman La-Roche Ltd, Janssen Global Services, LLC, Sage Therapeutics, Inc.
Richard S. Isaacson, MD
Director, Center for Brain Health
Florida Atlantic University
Boca Raton, FL
No relevant relationships reported.
- Cindy Davidson has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- Nick Lombardi has ownership interest in Vertex Pharmaceuticals.
- Libby Lurwick has nothing to disclose.
- Colleen Resnick has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Contrast how the slowing of Aβ plaques, as shown in recent clinical trial endpoints of slowing cognitive decline with immunotherapies, differs from current standard of care results in Alzheimer’s disease (AD)
- Recognize the positive impacts of earlier identification of AD in slowing the course of the disease
- Analyze how the mechanisms of action of newer investigational therapies relate to the molecular mechanisms that drive AD progression
- Analyze biomarkers for functional impairment, neuronal loss, and protein deposition that are assessable by neuroimaging or cerebrospinal fluid analysis for diagnosis, staging, and treatment outcomes
- Compare the monoclonal antibodies currently under study to treat AD
- Evaluate new agents that may be appropriate for patients with mild cognitive impairment (ie, the role of imaging)
This activity is designed to meet the educational needs of neurologists, primary care physicians, and other healthcare professionals that diagnose and treat patients with Alzheimer’s Disease.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.